EFFICACY AND TOLERABILITY OF BEVACIZUMAB (B) AND ERLOTINIB (E) AS FIRST-LINE THERAPY IN ASIAN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PHASE II TRIALC. Hsu, Y. Kang,T. S. Yang, W. Su, C. Shun, J. Sandoval-Tan,T. Chiou,K. Jin,C. Hsu,A. ChengANNALS OF ONCOLOGY（2010）引用 0|浏览8暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
